However, I see gene therapy companies having a rougher road ... I would set a few sell orders at key levels to book some profit and move my NTLA position to a “House Money” status to create ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

The chronic nature of Sickle Cell Disease and its impact on various organs can certainly drain money from one’s pocket or bank account over time. Since SCD affects multiple organs, the financial ...

Amazon has strong competitive moats and multiple ... The commercial launch of Casgevy is gaining momentum. This gene-editing therapy is a one-and-done treatment for the rare blood disorders ...

Conversations about personal mental health issues seem to be shifting. Meet three Brevard residents who believe it's time to shed the stigma.

Using its fully automated Lakhesys Benchtop Cell Factory TM, Astraveus has been able to demonstrate the potential of its unique microfluidic cell therapy processing approach ... system to the size of ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.